Group 1 - The report highlights the "spring market rally" effect, indicating that from the Central Economic Work Conference to the National People's Congress, the A-share market typically experiences a rally, with an average increase of 18.30% over 57 days based on historical data from 2009 to 2025 [4][7] - The report suggests that the market is expected to gradually enter a "spring market rally" phase, driven by increased liquidity and risk appetite, alongside favorable domestic policy expectations [4][7] - Key sectors to focus on include commercial aerospace, satellite industry, national defense, AI applications, and new consumption areas such as health, cultural tourism, and pet economy, which are expected to benefit from policy support [4][14][16] Group 2 - The macroeconomic recovery foundation remains to be solidified, with fixed asset investment declining by 2.6% year-on-year from January to November, indicating a need for policy measures to boost domestic demand [8][11] - The report notes that public budget expenditure increased by 1.4% year-on-year, with significant growth in social security, technology, and environmental protection spending, reflecting a focus on improving livelihoods and technological advancement [11] - The Japanese central bank's recent interest rate hike is expected to have limited impact on global markets, as the market had already priced in this increase, suggesting a continued trend of easing liquidity globally [12] Group 3 - The report provides an overview of A-share market performance, noting a slight increase in the Shanghai Composite Index by 0.03% and a decrease in the Shenzhen Component Index by 0.89% during the specified week [17] - The average daily trading volume in the A-share market was reported at 17,380.31 billion, reflecting a decrease of 10.12% compared to the previous week [17] - The report also highlights the performance of various sectors, with retail, non-bank financials, and beauty care showing the highest gains [17][20]

Core Viewpoint - Short-term fluctuations in A-shares are primarily influenced by external factors such as concerns over the AI bubble in the US stock market and interest rate hikes by the Bank of Japan, but A-shares are expected to resonate upward with global markets as US AI core company stock prices stabilize and the impact of the Bank of Japan's rate hike is limited [1] Industry Focus - Key industry focus areas include non-ferrous metals (silver, copper, tin, tungsten), high dividend stocks in Hong Kong, non-bank financials, AI (liquid cooling, optical communication), new energy (energy storage, solid-state batteries), innovative pharmaceuticals, and banking [1] Thematic Focus - Thematic investment areas to pay attention to are Hainan (duty-free), nuclear power, and ice and snow tourism [1]

Investment Rating - The report maintains an investment rating of "Outperform" with a target of A [7] Core Insights - The report highlights the positive results from Takeda's new generation oral TYK2 inhibitor, zasocitinib (TAK-279), for treating moderate to severe plaque psoriasis, with over 50% of participants achieving skin clearance or nearly clear skin (PASI 90) at week 16, and about 30% achieving complete clearance (PASI 100) [3][4] - The report suggests that there are multiple catalysts expected in the sector, including academic conferences and data readouts, which could provide investment opportunities [2] - The report emphasizes the potential of other TYK2 inhibitors, particularly Eifang Biopharma's D-2570, which has shown promising phase 2 clinical data [4][22] Summary by Sections Weekly New Drug Market Review - From December 15 to December 21, 2025, the top five gainers in the new drug sector were: Yahu Medicine (+12.03%), Cloudtop New Medicine (+9.32%), Aidi Pharmaceutical (+9.06%), Shiyao Group (+7.05%), and Ailis (+3.94%). The top five losers were: Chuangsheng Group (-16.03%), Beihai Kangcheng (-12.33%), Kedi (-11.88%), WuXi AppTec (-11.15%), and Nuocheng Jianhua (-10.99%) [1][17] Weekly Focus on Recommended Stocks - The report recommends focusing on companies with high certainty for overseas expansion, such as Sanofi Biopharma, Lianbang Pharmaceutical, and Kelun Biotech. It also highlights companies with potential overseas data catalysts, including Betta Pharmaceuticals, Hutchison China MediTech, and Ying'en Biopharma [2][21] Weekly New Drug Industry Analysis - Takeda's phase 3 clinical trials for zasocitinib have shown consistent results with previous phase 2 trials, indicating strong data reliability. The report also notes the potential for TYK2 inhibitors in treating Crohn's disease and ulcerative colitis [3][4][22] Weekly New Drug Application Approval & Acceptance - No new drug or new indication applications were approved domestically this week, but 11 new drug or new indication applications were accepted [5][26] Weekly New Drug Clinical Application Approval & Acceptance - This week, 55 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [11][28]

作者：财富情报局水寒 12月20日，以"破局·重构"为主题的雪球嘉年华在上海举行，神农投资总经理陈宇结合自己的投资策略 对2026年A股市场机会点进行了展望。 陈宇透露，今年其投资策略主要聚焦于创新药和Ai领域。关于创新药，陈宇在2024年就曾表达过看好观 点。当时他认为，2025年的创新药行业就相当于2005年的房地产行业。借鉴美日两国医药指数市场表 现，长远来看都很可观。 但同时，由于创新药赛道的特殊性，陈宇也建议二级市场投资者慎入，主要原因在于，创新药赛道是九 死一生的生意，再好的公司也可能因为一款创新药的研发失败而被替代，导致该赛道胜率低、赔率高。 除了创新药板块，另一个被陈宇大为看好的行业则是Ai应用领域。陈宇认为，2026年的Ai应用行业就相 当于2006年的房地产行业，将迎来集中爆发期。虽然当下Ai产业投资异常火热，但这几年资金主要集中 于算力和硬件等领域，明年无论是A股还是港股，Ai应用领域的投资都将孕育巨大机会。 此外，陈宇也对美联储降息及投资者颇为关切的量化发展等问题表达了自己的看法。 • 美联储降息影响。陈宇认为，宏观环境下，加息降息本质是钱多钱少的问题，市场结构分化下，对核 心产业如A ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

Core Viewpoint - A trend of "counter-market buying" is emerging in the Hong Kong stock market amidst ongoing fluctuations, with institutional investors recognizing the valuation opportunities and actively seizing the market pullback as a layout window [1][4]. Group 1: Fundraising and Investment Trends - Since October 10, at least 15 new Hong Kong-themed funds have announced early fundraising closures, covering various types including passive index funds, equity mixed funds, and QDII funds [2]. - The early fundraising trend is characterized by significantly shortened timelines, with some funds reducing their fundraising periods by over a month [2]. - Newly launched ETFs have established high stock positions quickly, indicating strong bullish signals, with some ETFs reaching stock positions of 69.53% and 63.32% before listing [3]. Group 2: Market Conditions and Valuation - The recent market adjustment has provided a favorable entry point for new funds, as many heavy-weight stocks have seen significant weekly declines while maintaining stable fundamentals [4]. - The Hang Seng Index's price-to-earnings ratio (TTM) is approximately 12 times, and the Hang Seng Tech Index's is about 23 times, both at historical low levels, reflecting institutional recognition of undervalued Hong Kong stocks [5]. Group 3: Market Challenges - The Hang Seng Index has dropped 5.85% and the Hang Seng Tech Index has fallen 18.01% since October 3, indicating a clear market correction [6]. - Factors contributing to the market adjustment include fluctuating liquidity expectations, concerns over the "AI bubble" in the U.S., increased IPO activity, and reduced southbound capital inflows [7][8]. Group 4: Long-term Outlook and Investment Opportunities - Despite short-term pressures, institutions maintain an optimistic long-term outlook for the Hong Kong stock market, predicting a "slow bull" market in 2026 with improved liquidity conditions [9]. - Key investment themes for 2026 include technology and high-end manufacturing, with a focus on sectors such as computing power, semiconductors, and consumer electronics [9]. - High dividend yield assets are also favored in a low-interest-rate environment, with institutions highlighting the value of leading copper and aluminum mining companies [9]. - The innovative drug and biotechnology sectors are seen as having significant investment opportunities due to industry acceleration and favorable policy adjustments [10].

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [32] Core Insights - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial)," which aims to systematically reshape existing pathological pricing projects, focusing on biopsy sampling, sample processing, slice replication, pathological staining, and diagnosis, establishing 28 pricing projects, 3 additional charges, and 2 expansion items. This refined pricing is expected to promote high-quality development in pathology and create new scenarios for the application of artificial intelligence-assisted technologies [4] - The guidelines will standardize the charging for digital pathological slices, solidifying the data foundation for large-scale applications of new scenarios. It includes "providing digital images of pathological slices" as an essential item for various pathological services, reflecting the costs of related resource consumption in pricing [4] - The guidelines also explore suitable forms to respond to the charging demands of artificial intelligence assistance, promoting the early application of AI in the pathology field by including "AI-assisted diagnosis" as an expansion item in the pricing structure [4] - The establishment of separate pricing projects for pathological diagnosis and sample testing emphasizes the value of technical services and supports precise medication guidance [4] Summary by Sections Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with significant single-product potential and price revaluation prospects, such as 3SBio, Kaineng Technology, and Qianhong Pharmaceutical. Additionally, it recommends companies leading in cutting-edge technology platform layouts, such as Dongcheng Pharmaceutical, Yuanda Pharmaceutical, and Kelun-Biotech [6] - In the CXO sector, it notes that R&D investment in pharmaceuticals is steadily increasing, and the innovation environment is expected to improve, suggesting attention to companies like WuXi AppTec, WuXi Biologics, and Boteng Co. [6] - For upstream companies, it indicates that quality enterprises are entering a harvest period with overseas layouts, recommending attention to Aopumai, Baipusais, and Baiyao [6] - In the medical device sector, it mentions that ongoing procurement will continue to advance, with equipment companies gradually digesting channel inventory, suggesting attention to Mindray Medical, United Imaging, and Kaili Medical [6] Industry News - The report highlights several key developments in the industry, including Takeda's TYK2 drug achieving positive results in Phase III studies, Baiyatai's anti-VEGF monoclonal antibody application for market approval, Sanofi's innovative therapy for hypertrophic cardiomyopathy receiving domestic approval, and Enhertu (Trastuzumab Deruxtecan) gaining FDA approval for a new indication [8][12][15][16]

Core Viewpoint - The Hong Kong stock market is expected to maintain a resilient performance through 2026, driven by improving liquidity and corporate earnings recovery, despite recent volatility in global markets [1][4]. Market Performance - As of December 19, the Hang Seng Index, Hang Seng Tech Index, and Hang Seng China Enterprises Index have increased by 28.07%, 22.63%, and 22.10% respectively since the beginning of the year, outperforming major global indices like the S&P 500 and Germany's DAX [1]. Future Outlook - Both buy-side and sell-side institutions have optimistic expectations for the Hong Kong stock market in 2026, anticipating a shift from valuation recovery to profit growth as the main driver of market performance [1][4]. - Dongwu Securities predicts that the Hong Kong stock market will continue to recover in 2026 due to several factors, including expected interest rate cuts by the Federal Reserve and improved corporate earnings [4]. Investment Strategies - Investment strategies for 2026 should focus on a "core + satellite" approach, with the core strategy centered on AI-related sectors and two satellite strategies targeting essential consumer industries and innovative companies creating new demand [7]. - The investment focus should include technology and cyclical sectors, with an emphasis on balancing growth and value styles [5][6]. Key Drivers - The anticipated recovery in corporate earnings is a crucial factor for the Hong Kong stock market, with expectations of further improvement in profitability [4][5]. - The market is expected to see continued inflows from both domestic and foreign investors, driven by a "wealth effect" [4]. Market Dynamics - The market is likely to experience a balanced style between large and small-cap stocks, with growth styles expected to dominate in 2026 [5]. - The research teams suggest a gradual or wave-like process for style switching, indicating that value and growth are not mutually exclusive [5]. Risk Considerations - Potential risks for the Hong Kong stock market include overly consensus-driven trading, significant fluctuations in U.S.-China monetary policy, and geopolitical influences [8].

Group 1 - The first Hong Kong stock information technology ETF, 159131, is set to shine, focusing on the "Hong Kong stock chip" industry chain [1][6] - The Hong Kong internet ETF, 513770, overlaps with major internet giants in Hong Kong and has a scale of over 10 billion [1] - The Hong Kong stock innovation drug ETF, 520880, is designed to cover the innovative drug sector with 100% pure innovation [2][6] Group 2 - The Hong Kong large-cap 30 ETF, 520560, is positioned to capture both high dividends and low volatility advantages [2][6] - The Hong Kong stock medical ETF, 159137, aims to comprehensively cover leading companies in the medical sector [2][6] - The Hong Kong stock automotive ETF, 520780, is set to be launched, focusing on scarce leading automotive companies in Hong Kong [2][6]

Market Overview - The A-share market showed a high-level fluctuation with the Shanghai Composite Index rising by 0.36%, the Shenzhen Component Index increasing by 0.66%, and the ChiNext Index up by 0.49% [1][13] - The total trading volume in the Shanghai and Shenzhen markets reached 1.73 trillion yuan, an increase of 704 billion yuan compared to the previous trading day, with over 4,400 stocks rising [1][13] - The Hong Kong market also saw gains, with the Hang Seng Index up by 0.75% and the Hang Seng Technology Index rising by 1.12% [1][13] Sector Performance - Main capital inflows were observed in sectors such as general equipment, automotive, and retail, while there were outflows from semiconductor, aerospace, and electronics sectors [2][14] - The consumer sector experienced a surge, particularly in retail and duty-free shops, while sectors like Hainan Free Trade Zone, nuclear fusion, rare earth permanent magnets, cross-strait integration, and intelligent driving concepts were active [2][14] Economic Data and Policy Impact - The U.S. inflation data for November showed a significant drop, with the overall CPI year-on-year falling to 2.74%, below the expected 3.06%, which has raised questions about data accuracy due to the government shutdown affecting previous data [3][15] - The Bank of Japan raised its target interest rate by 25 basis points to 0.75%, marking a 30-year high, which aligns with market expectations for ongoing monetary policy normalization [3][15] Innovation Drug Sector - The innovation drug sector is rebounding due to several catalysts, including a recovery in valuation after months of correction and upcoming key clinical data disclosures at the ASCO annual meeting in May 2026 [4][17] - The sector is entering a commercialization phase, with policy support extending from process optimization to full-chain empowerment, enhancing competitiveness [4][17] Hong Kong Technology Sector - The Hong Kong technology market has faced short-term pressure but is expected to rebound, with potential for capital inflows post-Christmas [6][18] - The market anticipates a recovery in January, although the extent of the rebound may be limited [6][18] Commodity Sector - The commodity sector, particularly non-ferrous metals, is performing well due to multiple factors, including a slowdown in U.S. CPI data, which has raised expectations for liquidity easing and supported metal prices [8][20] - The easing of rare earth export controls and a balanced supply-demand situation in industrial metals are also contributing to the sector's strength [8][20] Investment Opportunities - Investors are encouraged to consider ETFs focused on innovation drugs, Hong Kong technology, and commodities, as these sectors show potential for growth and recovery [4][21][22]